- Home
- FOLD vs PRKS Comparison
FOLD vs PRKS Comparison
Compare FOLD & PRKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- PRKS
- Stock Information
- Founded
- FOLD 2002
- PRKS 1959
- Country
- FOLD United States
- PRKS United States
- Employees
- FOLD N/A
- PRKS N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- PRKS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FOLD Health Care
- PRKS Health Care
- Exchange
- FOLD Nasdaq
- PRKS Nasdaq
- Market Cap
- FOLD 2.9B
- PRKS 2.8B
- IPO Year
- FOLD 2007
- PRKS 2013
- Fundamental
- Price
- FOLD $7.58
- PRKS $52.43
- Analyst Decision
- FOLD Strong Buy
- PRKS Buy
- Analyst Count
- FOLD 10
- PRKS 11
- Target Price
- FOLD $26.89
- PRKS $56.91
- AVG Volume (30 Days)
- FOLD 3.8M
- PRKS 931.1K
- Earning Date
- FOLD 07-31-2025
- PRKS 08-07-2025
- Dividend Yield
- FOLD N/A
- PRKS N/A
- EPS Growth
- FOLD N/A
- PRKS N/A
- EPS
- FOLD N/A
- PRKS 3.77
- Revenue
- FOLD $571,160,000.00
- PRKS $1,707,446,000.00
- Revenue This Year
- FOLD $20.98
- PRKS $0.97
- Revenue Next Year
- FOLD $20.74
- PRKS $2.30
- P/E Ratio
- FOLD N/A
- PRKS $13.94
- Revenue Growth
- FOLD 25.35
- PRKS N/A
- 52 Week Low
- FOLD $5.51
- PRKS $37.68
- 52 Week High
- FOLD $12.65
- PRKS $60.83
- Technical
- Relative Strength Index (RSI)
- FOLD 69.88
- PRKS 54.52
- Support Level
- FOLD $7.40
- PRKS $49.57
- Resistance Level
- FOLD $7.80
- PRKS $53.81
- Average True Range (ATR)
- FOLD 0.22
- PRKS 1.53
- MACD
- FOLD 0.01
- PRKS 0.02
- Stochastic Oscillator
- FOLD 87.61
- PRKS 61.90
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About PRKS United Parks & Resorts Inc. Common Stock
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.